Share this video  

ESMO 2022 | DATA: anastrozole in patients with HR+ breast cancer following adjuvant tamoxifen

Vivianne Tjan-Heijnen, MD, PhD, Maastricht University, Maastricht, the Netherlands, describes the trial design of the Phase III DATA trial (NCT00301457), which assessed various durations of anastrozole in patients with hormone receptor-positive breast cancer who were disease-free after 2-3 years of adjuvant tamoxifen. Patients were stratified by nodal status, hormone receptor status, HER2 status and duration of prior tamoxifen treatment. The primary endpoint was adapted disease-free survival (aDFS) and the secondary endpoint was adapted overall-survival (aOS), with the median adapted follow-up time being 10.1 years. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter